Find a Product

BioMAP® Phenotypic Profiling & Screening Services

Overview of the BioMAP Platform

BioMAP is the broadest, most physiologically relevant method to quickly and robustly determine the efficacy, safety, and mechanism of action (MOA) of candidate drug molecules to support their pipeline progression.

BioMAP Systems are composed of:
  • Over 60 human primary cell-based models of tissue and disease biology
  • Profiling with 100’s of clinically relevant protein biomarkers
  • Database of 4,500+ reference compounds and a suite of bioinformatics for in-depth prediction of safety and MOA

Request a Quote


 
   

BioMAP Phenotypic Profiling Accelerates Drug Candidates from Testing to Therapies

Unparalleled Comparison and Prioritization


Use BioMAP For:

  • Benchmarking to internal assets and approved standards of care.
  • Prioritization and rank ordering of candidate small molecules and biologics.
  • Lead Optimization and Screening of test agents based on physiologically relevant and predictive disease and tissue biology.
  • Combination Testing to evaluate drug combinations before moving in vivo.
 

Unmatched Characterization


Use BioMAP For:

Recent Webinars


 

  • Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing  Watch Webinar
  • Immuno-Oncology Drug Development: Profiling Immunomodulatory Biologics and Compounds in Human Primary Cell-Based Oncology Models. Watch Webinar
  • A Phenotypic Platform for Characterization of Drug Safety Mechanisms in Human Primary Cell Disease Models. Watch Webinar
 

Recent Client-DiscoverX Co-Publications


 

  • A. Hammitzsch, et al., “CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses,” Proceedings of the National Academy of Sciences, vol. 112, no. 34, pp. 10768–10773, 2015. Download PDF
  • P. Haselmayer, et al., “Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies,” Frontiers in Immunology, vol. 5, 2014. Read Article
  • J. L. Garrison, et al., “A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum,” Nature, vol. 436, no. 7048, pp. 285–289, 2005. Read Article

 
BioMAP Diversity PLUS Icon

Unbiased Characterization

Test Agents Across a Broad Range of Human Disease Models with Diversity PLUS®

The Diversity PLUS panel comprised of 12 BioMAP systems is used to inform on the potency, selectivity, safety, mechanism of action and disease indication of a test agent. A profile of biomarker activity of each test agent is generated and compared against the BioMAP reference database and 19 consensus mechanism class profiles of well-characterized drugs.

Learn More
 

 


BioMAP Services Listing

Combo ELECT - Maximize the impact of your compounds in combination
Diversity PLUS - Test agents across a broad range of human disease models
Fibrosis Panel - Model fibrosis in various tissue environments
Oncology Systems - Model complexity of tumor microenvironments
Systems ELECT - Create your own customized BioMAP panel
T Cell/Autoimmune Panel - Model the adaptive immune cell microenvironment
Tox Alert for Diversity Plus - Clinically relevant toxicity insights before entering the clinic
 

BioMAP Resources

What is BioMAP?

FAQ

Recommended Benchmarks
 

Webinars

BioMAP® Systems for Investigative Toxicology Watch Webinar
Introduction to BioMAP®: Primary Human Cell Systems for Drug Discovery Watch Webinar
Leveraging Predictive Human Adaptive Immune Cell Models for Drug Discovery Watch Webinar

Application Specific Case Studies

Secondary Activity of an Adrenergic Receptor Antagonist Read Case Study
Economic Impact of BioMAP® Profiling Read Case Study
Explaining a Clinical Adverse Event Read Case Study
Differentiating p38MAPK Inhibitors Read Case Study